Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
When the healthcare giant reports earnings Thursday morning, investors will be looking to see if Brian Thompson’s death and ...
The wildfires that have devastated large parts of Los Angeles County have drawn fresh attention to the struggles many ...
Rio Tinto, the world's No. 2 mining company by market value, on Thursday reported a drop in iron-ore production and shipments from its Australian mines. Fourth-quarter and full-year output and exports ...
My parents, my sister and I — a middle-aged woman — are from overseas, but I’ve lived in the U.S. for more than half of my ...
Azul and Abra, the majority investors of airlines Gol and Avianca, on Wednesday said they signed a non-binding Memorandum of Understanding to combine their businesses in Brazil.
Serina Therapeutics sold its UniverXome subsidiary in a deal finalized on Dec. 23. The biotechnology company said the transaction eliminated $11.2 million in associated subsidiary-level debt, allowing ...
Shares of SPAR Group Inc. were rising in the after-hours market after the company said it received an amended and restated commitment letter for financing required under its merger agreement with ...
Synovus Financial posted higher revenue and profit in the fourth quarter, boosted by lower funding costs and stronger lending relationships. The Columbus, Ga., bank-holding company on Wednesday ...
Incyte and Syndax Pharmaceutical said the Food and Drug Administration approved their graft disease treatment Niktimvo antibody in nine milligram and 22 milligram vial sizes.
The uranium company said Wednesday that it now owns 203.4 million of the Anfield Energy's shares. This stake represents roughly 18% of the Canadian energy company's outstanding shares on a non-diluted ...
Shares of Silexion Therapeutics surged after the company released what it called promising preclinical data for its treatment of pancreatic cancer. The stock jumped 68%, to $2.61, in after-hours ...